Accession Number: | 0001209191-20-002341 |
Date: | 2020-01-05 |
Issuer: | EAGLE PHARMACEUTICALS, INC. (EGRX) |
Original Submission Date: |
GLENNING ROBERT
C/O EAGLE PHARMACEUTICALS, INC.
50 TICE BLVD., SUITE 315
WOODCLIFF LAKE, NJ 07677
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 59.795 | 2020-01-05 | deemed execution date | A | 10,000 (a) | 2030-01-04 | common stock 10,000 | $59.80 | 10,000 | direct |
ID | footnote |
---|---|
f1 | the option fully vests on january 5, 2021, subject to the reporting person's continuous service with the issuer as of the vesting date. |